KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

AbbVie (ABBV) Shares Outstanding (2016 - 2026)

AbbVie has reported Shares Outstanding over the past 13 years, most recently at $1.8 billion for Q4 2025.

  • Quarterly Shares Outstanding changed 0.17% to $1.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, changed 0.17% year-over-year, with the annual reading at $1.8 billion for FY2025, 0.17% changed from the prior year.
  • Shares Outstanding was $1.8 billion for Q4 2025 at AbbVie, up from $1.8 billion in the prior quarter.
  • Over five years, Shares Outstanding peaked at $1.8 billion in Q4 2025 and troughed at $1.8 billion in Q1 2023.
  • The 5-year median for Shares Outstanding is $1.8 billion (2021), against an average of $1.8 billion.
  • Year-over-year, Shares Outstanding increased 19.57% in 2021 and then decreased 0.17% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $1.8 billion in 2021, then grew by 0.06% to $1.8 billion in 2022, then dropped by 0.17% to $1.8 billion in 2023, then dropped by 0.06% to $1.8 billion in 2024, then rose by 0.17% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Shares Outstanding are $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.8 billion (Q2 2025).